For: | Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol 2017; 23(44): 7899-7905 [PMID: 29209131 DOI: 10.3748/wjg.v23.i44.7899] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v23/i44/7899.htm |
Number | Citing Articles |
1 |
Shahid Sarwar, Shandana Tarique, Abdul Aleem, Anwaar A. Khan. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan. European Journal of Gastroenterology & Hepatology 2019; 31(8): 1035 doi: 10.1097/MEG.0000000000001376
|
2 |
Tayyab Saeed Akhter. Hepatitus C Guidelines. Journal of Rawalpindi Medical College 2024; 1(1) doi: 10.37939/jrmc.v1i1.2533
|
3 |
Saba Khaliq, Syed Raza. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan. Medicina 2018; 54(5): 80 doi: 10.3390/medicina54050080
|
4 |
Massimo Giuseppe Colombo, Erkin Isakovich Musabaev, Umed Yusupovich Ismailov, Igor A Zaytsev, Alexander V Nersesov, Igor Anatoliyevich Anastasiy, Igor Alexandrovich Karpov, Olga A Golubovska, Kulpash S Kaliaskarova, Ravishankar AC, Sanjay Hadigal. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World Journal of Gastroenterology 2019; 25(29): 3897-3919 doi: 10.3748/wjg.v25.i29.3897
|
5 |
Uzma Saleem, Nosheen Aslam, Rida Siddique, Shabnoor Iqbal, Maria Manan. Hepatitis C virus: Its prevalence, risk factors and genotype distribution in Pakistan. European Journal of Inflammation 2022; 20: 1721727X2211443 doi: 10.1177/1721727X221144391
|
6 |
Attiya S Rahman, Muhammad Amir, Qaiser Jamal, Mehwish Riaz , Komal Fareed, Muhammad Siddiqui. End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir. Cureus 2023; doi: 10.7759/cureus.38833
|